Cumberland Pharmaceuticals Inc (CPIX) - Total Assets
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) holds total assets worth $71.00 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Cumberland Pharmaceuticals Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Cumberland Pharmaceuticals Inc - Total Assets Trend (2005–2025)
This chart illustrates how Cumberland Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See Cumberland Pharmaceuticals Inc (CPIX) net assets for net asset value and shareholders' equity analysis.
Cumberland Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cumberland Pharmaceuticals Inc's total assets of $71.00 Million consist of 48.2% current assets and 51.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.9% |
| Accounts Receivable | $16.94 Million | 22.1% |
| Inventory | $6.23 Million | 8.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.03 Million | 18.3% |
| Goodwill | $914.00K | 1.2% |
Asset Composition Trend (2005–2025)
This chart illustrates how Cumberland Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CPIX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cumberland Pharmaceuticals Inc's current assets represent 48.2% of total assets in 2025, a decrease from 84.5% in 2005.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2025, down from 54.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 22.1% of total assets.
Cumberland Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Cumberland Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Cumberland Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.95 | 1.25 | 2.50 |
| Quick Ratio | 0.79 | 1.09 | 1.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.70 Million | $6.36 Million | $28.03 Million |
Cumberland Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Cumberland Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.24 |
| Latest Market Cap to Assets Ratio | 0.89 |
| Asset Growth Rate (YoY) | 1.6% |
| Total Assets | $76.82 Million |
| Market Capitalization | $68.47 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cumberland Pharmaceuticals Inc's assets close to their book value (0.89x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Cumberland Pharmaceuticals Inc's assets grew by 1.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cumberland Pharmaceuticals Inc (2005–2025)
The table below shows the annual total assets of Cumberland Pharmaceuticals Inc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $76.82 Million | +1.64% |
| 2024-12-31 | $75.58 Million | -7.57% |
| 2023-12-31 | $81.78 Million | -12.00% |
| 2022-12-31 | $92.93 Million | +10.02% |
| 2021-12-31 | $84.46 Million | -12.44% |
| 2020-12-31 | $96.46 Million | -7.73% |
| 2019-12-31 | $104.55 Million | -7.23% |
| 2018-12-31 | $112.69 Million | +20.87% |
| 2017-12-31 | $93.23 Million | -0.18% |
| 2016-12-31 | $93.40 Million | +1.62% |
| 2015-12-31 | $91.92 Million | -3.65% |
| 2014-12-31 | $95.41 Million | +8.89% |
| 2013-12-31 | $87.61 Million | -11.14% |
| 2012-12-31 | $98.59 Million | +3.22% |
| 2011-12-31 | $95.52 Million | +3.76% |
| 2010-12-31 | $92.05 Million | -11.25% |
| 2009-12-31 | $103.72 Million | +233.31% |
| 2008-12-31 | $31.12 Million | +7.61% |
| 2007-12-31 | $28.92 Million | +9.20% |
| 2006-12-31 | $26.48 Million | +160.30% |
| 2005-12-31 | $10.17 Million | -- |
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso… Read more